BCL2A1 and hepatocellular adenoma: Given that NSAIDs are neither safe nor durable therapeutic options during pregnancy due to fetal renal toxicity [29] and no other anti-inflammatory treatments for acute HCA are currently available, these findings further highlight the potential of BCL2A1 as a valuable therapeutic target for this condition.